A more aggressive FTC is starting to target drug mergers and industry middlemen
Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.
Tribune News Service ·